The Cost-Effectiveness of Tolvaptan for the Treatment of Hyponatraemia Secondary To Syndrome Of Inappropriate Antidiuretic Hormone Secretion in Sweden.
| Autor: | Trueman D; Decision Resources Group, London, UK., Robinson P; Otsuka Pharmaceutical Europe Ltd, Wexham, UK., Dale P; Otsuka Pharmaceutical Europe Ltd, Wexham, UK., O'Reilly K; Otsuka Pharmaceutical Europe Ltd, Wexham, UK., Lundberg J; Otsuka Pharma Scandinavia, Stockholm, Sweden., Jamookeeah C; Otsuka Pharmaceutical Europe Ltd, Wexham, UK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2014 Nov; Vol. 17 (7), pp. A350. Date of Electronic Publication: 2014 Oct 26. |
| DOI: | 10.1016/j.jval.2014.08.728 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect